TDC
VNDA icon

Thompson Davis & Co’s Vanda Pharmaceuticals VNDA Stock Holding History

Thompson Davis & Co’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-350
Closed -$6K – 1210
2017
Q2 		$6K Buy
+350
New +$5.04K 0.01% 811

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Thompson Davis & Co's VNDA Position: Q3 2017 in Review

Thompson Davis & Co sold out of Vanda Pharmaceuticals (VNDA) in Q3 2017, closing a stake of 350 shares — an estimated $6K sold.

Thompson Davis & Co first reported a position in VNDA in Q2 2017 and held it in 1 quarter. The position peaked at $6K in Q2 2017. 137 funds tracked by Wall St. Rank hold VNDA as of Q3 2017.

  • Thompson Davis & Co reported no remaining Vanda Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 350 Vanda Pharmaceuticals shares in Q3 2017, an estimated $6K.
  • Thompson Davis & Co first reported a position in Vanda Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Thompson Davis & Co's Vanda Pharmaceuticals position peaked at $6K in Q2 2017.
  • 137 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2017.

Based on Thompson Davis & Co's 13F filing for Q3 2017, filed 30 Oct 2017.